Resumen
Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation ALK inhibitors can be considered.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 196-200 |
Número de páginas | 5 |
Publicación | Current Oncology |
Volumen | 23 |
N.º | 3 |
DOI | |
Estado | Published - 2016 |
Publicado de forma externa | Sí |
Nota bibliográfica
Publisher Copyright:© 2016 Multimed Inc.
ASJC Scopus Subject Areas
- Oncology